Eledon Pharmaceuticals, Inc. SEC filings ELDN
Eledon Pharmaceuticals, Inc. has 614 filings in SEC EDGAR's recent list, going back to Jun 18, 2007. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 30, 2026 | — |
| S-8 | Employee stock plan registration | Sep 4, 2026 | — |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 4 | Insider transaction | Aug 4, 2026 | Jul 31, 2026 |
| 4 | Insider transaction | Aug 4, 2026 | Jul 31, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 31, 2026 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| EFFECT | Filing | May 11, 2026 | — |
| CORRESP | Letter to the SEC | May 7, 2026 | — |
| UPLOAD | Letter from the SEC | May 7, 2026 | — |
| S-3 | Shelf registration | May 1, 2026 | — |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 18, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 27, 2026 | — |
| PRE 14A | Preliminary proxy statement | Apr 21, 2026 | Jun 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 26, 2026 | — |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2026 | Mar 19, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 21, 2026 | — |
| 4 | Insider transaction | Jan 16, 2026 | Jan 10, 2026 |
| 4 | Insider transaction | Jan 16, 2026 | Jan 10, 2026 |
| 4 | Insider transaction | Jan 16, 2026 | Jan 10, 2026 |
| 4 | Insider transaction | Jan 16, 2026 | Jan 10, 2026 |
| 4 | Insider transaction | Jan 16, 2026 | Jan 10, 2026 |
| 4 | Insider transaction | Jan 16, 2026 | Jan 10, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Jan 2, 2026 | Dec 30, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 24, 2025 | — |
| 8-K |
Current report
Results of operations
|
Nov 14, 2025 | Nov 14, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Material agreement
|
Nov 13, 2025 | Nov 12, 2025 |
| 424B5 | Prospectus supplement | Nov 13, 2025 | — |
| 424B5 | Prospectus supplement | Nov 12, 2025 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 7, 2025 | Nov 6, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 10-Q/A | Amended quarterly report | Aug 14, 2025 | Mar 31, 2025 |
| 10-K/A | Amended annual report | Aug 14, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Restatement
|
Aug 14, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 6, 2025 | Aug 6, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 29, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 17, 2025 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 12, 2025 | Jun 10, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 10, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2025 | Jun 10, 2025 |
| 8-K/A |
Amended current report
Auditor change
|
Apr 14, 2025 | Apr 1, 2025 |
| 8-K |
Current report
Auditor change
|
Apr 7, 2025 | Apr 1, 2025 |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2025 | Mar 20, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 4 | Insider transaction | Jan 13, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 20, 2024 | Dec 16, 2024 |
| 4 | Insider transaction | Nov 22, 2024 | Nov 21, 2024 |
| 4 | Insider transaction | Nov 22, 2024 | Nov 21, 2024 |
| 4 | Insider transaction | Nov 22, 2024 | Nov 21, 2024 |
| 4 | Insider transaction | Nov 22, 2024 | Nov 21, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 5, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 5, 2024 | — |
| 4 | Insider transaction | Oct 31, 2024 | Oct 29, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 31, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 31, 2024 | — |
| 424B5 | Prospectus supplement | Oct 30, 2024 | — |
| 424B5 | Prospectus supplement | Oct 30, 2024 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 30, 2024 | Oct 29, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2024 | Oct 29, 2024 |
| EFFECT | Filing | Oct 2, 2024 | — |
| 8-K |
Current report
Unregistered share sale
|
Oct 1, 2024 | Sep 30, 2024 |
| CORRESP | Letter to the SEC | Sep 30, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2024 | — |
| 8-K |
Current report
Material agreement
|
Sep 20, 2024 | Sep 20, 2024 |
| S-3 | Shelf registration | Sep 20, 2024 | — |
| 10-Q | Quarterly report | Aug 19, 2024 | Jun 30, 2024 |
| 10-Q/A | Amended quarterly report | Aug 19, 2024 | Mar 31, 2024 |
| 10-K/A | Amended annual report | Aug 19, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations, Restatement
|
Aug 14, 2024 | Aug 13, 2024 |
| NT 10-Q | Filing | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Auditor change
|
Jul 12, 2024 | Jul 10, 2024 |
| 8-K |
Current report
Unregistered share sale
|
Jul 10, 2024 | Jul 8, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Jul 10, 2024 | Jul 10, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 424B3 | Prospectus | Jun 6, 2024 | — |
| EFFECT | Filing | Jun 5, 2024 | — |
| CORRESP | Letter to the SEC | Jun 3, 2024 | — |
| UPLOAD | Letter from the SEC | May 30, 2024 | — |
| ARS | Annual report to shareholders | May 30, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | May 30, 2024 | — |
| DEF 14A | Proxy statement | May 30, 2024 | Jul 10, 2024 |
| S-3 | Shelf registration | May 24, 2024 | — |
| D | Filing | May 23, 2024 | — |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 4 | Insider transaction | May 13, 2024 | May 9, 2024 |
| 8-K |
Current report
Results of operations
|
May 13, 2024 | May 9, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 7, 2024 | May 6, 2024 |
| 10-K/A | Amended annual report | Apr 26, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 28, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 2, 2023 | Nov 2, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Oct 2, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Oct 2, 2023 |
| 3 | Initial insider ownership | Oct 2, 2023 | Oct 1, 2023 |
| 3 | Initial insider ownership | Oct 2, 2023 | Oct 2, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 21, 2023 | Sep 20, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 13, 2023 | Sep 11, 2023 |
| S-8 | Employee stock plan registration | Aug 11, 2023 | — |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 22, 2023 | Jun 21, 2023 |
| 424B3 | Prospectus | Jun 8, 2023 | — |
| EFFECT | Filing | Jun 2, 2023 | — |
| CORRESP | Letter to the SEC | May 31, 2023 | — |
| UPLOAD | Letter from the SEC | May 24, 2023 | — |
| D | Filing | May 22, 2023 | — |
| S-3 | Shelf registration | May 18, 2023 | — |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 4 | Insider transaction | May 9, 2023 | May 5, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| 4 | Insider transaction | May 2, 2023 | May 1, 2023 |
| DEF 14A | Proxy statement | May 1, 2023 | — |
| ARS | Annual report to shareholders | May 1, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
May 1, 2023 | Apr 26, 2023 |
| 10-K | Annual report | Mar 30, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2023 | Mar 30, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 4 | Insider transaction | Feb 2, 2023 | Feb 1, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 4 | Insider transaction | Nov 23, 2022 | Nov 23, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2022 | Nov 14, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2022 | Jun 22, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 31, 2022 | May 31, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 21, 2022 |
| 10-K | Annual report | Mar 24, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2022 | Mar 24, 2022 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2022 | — |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Feb 2, 2022 | Feb 1, 2022 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELDN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404281
- Former names
- Eledon Pharmaceuticals, Inc. (until Oct 30, 2026); Novus Therapeutics, Inc. (until Dec 22, 2020); Tokai Pharmaceuticals Inc (until May 4, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.